Literature DB >> 19122874

Modeling cancer patient populations in mice: complex genetic and environmental factors.

Daniel R Radiloff1, Erica S Rinella, David W Threadgill.   

Abstract

Genetic differences among individuals contribute to differential susceptibility to cancer and, undoubtedly, to variable efficacy and toxicity of pharmacological-based therapeutics. Many of the specific molecular processes involved in human tumorigenesis have been elucidated and accurately modeled in mice. However, the current models used for drug testing do not accurately predict how new treatments will fare in clinical trials. More sophisticated models that treat cancer as a complex disease present within heterogenous patient populations will provide better predictive power to identify patients that may benefit from specific therapies or that may develop potential drug-induced toxicities.

Entities:  

Year:  2008        PMID: 19122874      PMCID: PMC2516949          DOI: 10.1016/j.ddmod.2007.06.004

Source DB:  PubMed          Journal:  Drug Discov Today Dis Models        ISSN: 1740-6757


  35 in total

1.  Intellectual property. DuPont ups ante on use of Harvard's OncoMouse.

Authors:  Eliot Marshall
Journal:  Science       Date:  2002-05-17       Impact factor: 47.728

Review 2.  Pathology of mouse models of intestinal cancer: consensus report and recommendations.

Authors:  Gregory P Boivin; Kay Washington; Kan Yang; Jerrold M Ward; Theresa P Pretlow; Robert Russell; David G Besselsen; Virginia L Godfrey; Tom Doetschman; William F Dove; Henry C Pitot; Richard B Halberg; Steven H Itzkowitz; Joanna Groden; Robert J Coffey
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

3.  Realistic rodents? Debate grows over new mouse models of cancer.

Authors:  Ken Garber
Journal:  J Natl Cancer Inst       Date:  2006-09-06       Impact factor: 13.506

4.  A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice.

Authors:  Minh D To; Jesus Perez-Losada; Jian-Hua Mao; Jeff Hsu; Tyler Jacks; Allan Balmain
Journal:  Nat Genet       Date:  2006-07-02       Impact factor: 38.330

5.  A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice.

Authors:  H L Newmark; K Yang; M Lipkin; L Kopelovich; Y Liu; K Fan; H Shinozaki
Journal:  Carcinogenesis       Date:  2001-11       Impact factor: 4.944

6.  Strain differences in haematological response to chloramphenicol succinate in mice: implications for toxicological research.

Authors:  M F Festing; P Diamanti; J A Turton
Journal:  Food Chem Toxicol       Date:  2001-04       Impact factor: 6.023

Review 7.  Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.

Authors:  Susan Kasper
Journal:  J Cell Biochem       Date:  2005-02-01       Impact factor: 4.429

8.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

9.  Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice.

Authors:  C J Quaife; C A Pinkert; D M Ornitz; R D Palmiter; R L Brinster
Journal:  Cell       Date:  1987-03-27       Impact factor: 41.582

10.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

View more
  8 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains.

Authors:  Lori D Dwyer-Nield; Jay McQuillan; Annie Hill-Baskin; Richard A Radcliffe; Ming You; Joseph H Nadeau; Alvin M Malkinson
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

3.  Electroporation markedly improves Sleeping Beauty transposon-induced tumorigenesis in mice.

Authors:  S Jung; H-J Choi; H-K Park; W Jo; S Jang; J-E Ryu; W-J Kim; E-S Yu; W-C Son
Journal:  Cancer Gene Ther       Date:  2014-07-04       Impact factor: 5.987

4.  Pre-clinical drug prioritization via prognosis-guided genetic interaction networks.

Authors:  Jianghui Xiong; Juan Liu; Simon Rayner; Ze Tian; Yinghui Li; Shanguang Chen
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

Review 5.  Tumor microenvironment: a new treatment target for cancer.

Authors:  Ming-Ju Tsai; Wei-An Chang; Ming-Shyan Huang; Po-Lin Kuo
Journal:  ISRN Biochem       Date:  2014-04-10

6.  Sleeping Beauty transposon system harboring HRAS, c-Myc and shp53 induces sarcomatoid carcinomas in mouse skin.

Authors:  Sunyoung Jung; Simon Weonsang Ro; Geunyoung Jung; Hye-Lim Ju; Eun-Sil Yu; Woo-Chan Son
Journal:  Oncol Rep       Date:  2013-01-31       Impact factor: 3.906

7.  STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.

Authors:  Florence Meyer-Losic; Simon P Newman; Joanna M Day; Michael J Reed; Philip G Kasprzyk; Atul Purohit; Paul A Foster
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

8.  Panx3 links body mass index and tumorigenesis in a genetically heterogeneous mouse model of carcinogen-induced cancer.

Authors:  Kyle D Halliwill; David A Quigley; Hio Chung Kang; Reyno Del Rosario; David Ginzinger; Allan Balmain
Journal:  Genome Med       Date:  2016-08-09       Impact factor: 11.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.